Cantor Fitzgerald Maintains Overweight on Insmed, Lowers Price Target to $46
Cantor Fitzgerald analyst Jennifer Kim maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $49 to $46.
HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $52 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $52 price target.
Insmed Q4 EPS $(1.21) Misses $(1.04) Estimate, Sales $59.30M Miss $62.28M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.04) by 16.35 percent. This is a 27.37 percent decrease over losses of $(0.95) per share from the same
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Barclays Maintains Overweight on Insmed, Lowers Price Target to $35
Barclays analyst Leon Wang maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $37 to $35.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Mizuho Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $28
Mizuho analyst Graig Suvannavejh initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $28.
Analyst Ratings for Insmed
Over the past 3 months, 5 analysts have published their opinion on Insmed (NASDAQ:INSM) stock. These analysts are…
